Influenza treatment with neuraminidase inhibitors: Cost-effectiveness and cost-utility in healthy adults in the United Kingdom

We assessed the cost-effectiveness and cost-utility of treating influenza with neuraminidase inhibitors (oseltamivir and zanamivir) from a health care payer’s and societal perspective in the United Kingdom. A simulation model was developed to predict morbidity and mortality due to influenza and its...

Descripción completa

Detalles Bibliográficos
Autores principales: Sander, Beate, Gyldmark, Marlene, Hayden, Frederick G., Morris, James, Mueller, Elvira, Bergemann, Rito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer-Verlag 2005
Materias:
Original Papers
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087894/
https://www.ncbi.nlm.nih.gov/pubmed/15875227
http://dx.doi.org/10.1007/s10198-005-0297-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7087894/
https://www.ncbi.nlm.nih.gov/pubmed/15875227
http://dx.doi.org/10.1007/s10198-005-0297-y

Ejemplares similares